ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
A narrative review of serum biomarkers in progressive supranuclear palsy, corticobasal syndrome, and related disorders.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome.International journal of molecular sciences · 2025Review
- Seed Amplification Assay for α-Synuclein: Diagnostic Applications in Synucleinopathies.International journal of molecular sciences · 2025Review
- Increased tau-induced inflammatory responses are associated with a greater degree of atherosclerosis in progressive supranuclear palsy.Frontiers in aging neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review evaluates the diagnostic potential of serum biomarkers for progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and related neurodegenerative diseases. Hyperphosphorylated tau species (p-tau), particularly p-tau217 and p-tau181, show promise in distinguishing PSP and CBS from other neurodegenerative diseases, though not from each other. While serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) exhibit limited individual utility, their combination with p-tau species enhances diagnostic accuracy. Other genome-associated, inflammatory, metabolic biomarkers, and neuropeptides yield interesting though inconsistent results. The majority of serum biomarkers yielded non-specific results in differentiating PSP and/or CBS from each other and from other related neurodegenerative diseases. Future large-scale, multi-center studies with autopsy confirmation in early-stage patients are essential for developing reliable biomarker panels. Direct comparative studies of PSP and CBS subtypes are also necessary for accurate phenotypic discrimination.
Indexed as
Identifiers
40445321What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.